Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:54:20 EST Tue 13 Jan 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:SMMT - SUMMIT THERAPEUTICS INC - https://www.summitplc.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SMMT - Q0.116.78·17.290.817.04-2.64-13.48,789.3149,14447,38219.855  19.90  16.4736.91  15.55Jan 12Jan 1215 min RT 2¢

Recent Trades - Last 10 of 47382
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 06:15U:SMMTNews ReleaseSummit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)
2026-01-12 06:00U:SMMTNews ReleaseSummit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
2026-01-09 20:16U:SMMTNews ReleaseSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-06 07:30U:SMMTNews ReleaseSummit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-05 16:30U:SMMTNews ReleaseSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07 09:00U:SMMTNews ReleaseIvonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
2025-11-04 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at Upcoming Investor Conferences
2025-10-31 07:00U:SMMTNews ReleaseOverall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
2025-10-22 08:00U:SMMTNews ReleaseSummit Therapeutics Raises $500 Million in Private Placement
2025-10-20 06:45U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
2025-10-19 10:30U:SMMTNews ReleaseIvonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
2025-10-17 07:00U:SMMTNews ReleaseSummit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
2025-10-15 07:00U:SMMTNews ReleaseSummit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
2025-09-24 16:30U:SMMTNews ReleaseSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-24 07:00U:SMMTNews ReleaseHARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
2025-09-07 03:30U:SMMTNews ReleaseLonger-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
2025-09-03 07:00U:SMMTNews ReleaseSummit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
2025-08-14 07:00U:SMMTNews ReleaseIvonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
2025-08-11 17:03U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
2025-06-30 08:00U:SMMTNews ReleaseRevolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors